NASDAQ:IMGN ImmunoGen Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ImmunoGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.07 -0.03 (-0.73 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$3.90Now: $4.07▼$4.1950-Day Range$3.44MA: $3.84▼$4.3752-Week Range$1.95Now: $4.07▼$7.07Volume3.12 million shsAverage Volume2.75 million shsMarket Capitalization$710.39 millionP/E RatioN/ADividend YieldN/ABeta2.16 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. ImmunoGen, Inc. has collaborations with Roche, Amgen/Oxford BioTherapeutics, sanofi-aventis U. S. LLC, Biotest AG, Bayer HealthCare AG, Novartis Institutes for BioMedical Research, Inc., CytomX Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Fusion Pharmaceuticals Inc., Debiopharm International SA, Jazz Pharmaceuticals Ireland Limited, and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingImmunoGen has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.50, ImmunoGen has a forecasted upside of 158.0% from its current price of $4.07.Amount of Analyst CoverageImmunoGen has only been the subject of 2 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesImmunoGen has received 441 “outperform” votes. (Add your “outperform” vote.)Underperform VotesImmunoGen has received 479 “underperform” votes. (Add your “underperform” vote.)Community SentimentImmunoGen has received 52.07% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about ImmunoGen and other stocks. Vote “Outperform” if you believe IMGN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IMGN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldImmunoGen does not currently pay a dividend.Dividend GrowthImmunoGen does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ImmunoGen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.38% of the stock of ImmunoGen is held by insiders.Percentage Held by Institutions79.37% of the stock of ImmunoGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for ImmunoGen are expected to decrease in the coming year, from ($0.70) to ($0.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ImmunoGen is -9.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ImmunoGen is -9.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.36 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:IMGN Previous Symbol CUSIP45253H10 CIK855654 Webwww.immunogen.com Phone781-895-0600Debt Debt-to-Equity RatioN/A Current Ratio2.66 Quick Ratio2.66Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$82.27 million Price / Sales8.63 Cash FlowN/A Price / Cash FlowN/A Book Value($0.51) per share Price / Book-7.98Profitability EPS (Most Recent Fiscal Year)($0.70) Net Income$-104,130,000.00 Net Margins-81.34% Return on EquityN/A Return on Assets-26.59%Miscellaneous Employees296 Outstanding Shares174,542,000Market Cap$710.39 million Next Earnings Date11/6/2020 (Estimated) OptionableOptionable $4.07 -0.03 (-0.73 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive IMGN News and Ratings via Email Sign-up to receive the latest news and ratings for IMGN and its competitors with MarketBeat's FREE daily newsletter. ImmunoGen (NASDAQ:IMGN) Frequently Asked Questions How has ImmunoGen's stock price been impacted by Coronavirus (COVID-19)? ImmunoGen's stock was trading at $3.37 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, IMGN shares have increased by 20.8% and is now trading at $4.07. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of ImmunoGen? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ImmunoGen. When is ImmunoGen's next earnings date? ImmunoGen is scheduled to release its next quarterly earnings announcement on Friday, November 6th 2020. View our earnings forecast for ImmunoGen. How were ImmunoGen's earnings last quarter? ImmunoGen, Inc. (NASDAQ:IMGN) posted its quarterly earnings data on Friday, July, 31st. The biotechnology company reported ($0.14) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.18) by $0.04. The biotechnology company earned $15.03 million during the quarter, compared to the consensus estimate of $14.29 million. View ImmunoGen's earnings history. What guidance has ImmunoGen issued on next quarter's earnings? ImmunoGen updated its FY 2020 Pre-Market earnings guidance on Friday, July, 31st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $60-65 million, compared to the consensus revenue estimate of $63.12 million. What price target have analysts set for IMGN? 5 Wall Street analysts have issued 1-year price targets for ImmunoGen's shares. Their forecasts range from $9.00 to $12.00. On average, they expect ImmunoGen's stock price to reach $10.50 in the next twelve months. This suggests a possible upside of 158.0% from the stock's current price. View analysts' price targets for ImmunoGen. Are investors shorting ImmunoGen? ImmunoGen saw a increase in short interest during the month of August. As of August 14th, there was short interest totaling 17,770,000 shares, an increase of 9.7% from the July 30th total of 16,200,000 shares. Based on an average daily trading volume, of 2,310,000 shares, the days-to-cover ratio is presently 7.7 days. View ImmunoGen's Short Interest. Who are some of ImmunoGen's key competitors? Some companies that are related to ImmunoGen include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Immunomedics (IMMU), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX) and Exelixis (EXEL). View all competitors. What other stocks do shareholders of ImmunoGen own? Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Pfizer (PFE), Immunomedics (IMMU), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Advanced Micro Devices (AMD), AbbVie (ABBV), Dynavax Technologies (DVAX), Opko Health (OPK) and Energy Transfer LP Unit (ET). Who are ImmunoGen's key executives? ImmunoGen's management team includes the following people: Mr. Mark J. Enyedy, Pres, CEO, Interim Principal Financial Officer & Director (Age 55)Dr. Richard J. Gregory, Exec. VP & Chief Scientific Officer (Age 61)Mr. Craig Barrows, Exec. VP, Gen. Counsel & Sec. (Age 64)Dr. Anna Berkenblit, VP & Chief Medical Officer (Age 49)Mr. David G. Foster, VP of Fin. & Chief Accounting Officer What is ImmunoGen's stock symbol? ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN." Who are ImmunoGen's major shareholders? ImmunoGen's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.54%), Goldman Sachs Group Inc. (0.99%), Charles Schwab Investment Management Inc. (0.66%), Two Sigma Advisers LP (0.63%), Pinnacle Associates Ltd. (0.62%) and Nuveen Asset Management LLC (0.56%). Company insiders that own ImmunoGen stock include Anna Berkenblit, Craig Barrows, David G Foster, Mark Alan Goldberg, Mark J Enyedy, Richard J Gregory and Thomas Ryll. View institutional ownership trends for ImmunoGen. Which institutional investors are selling ImmunoGen stock? IMGN stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Nuveen Asset Management LLC, Federated Hermes Inc., Bank of America Corp DE, UBS Group AG, Healthcare of Ontario Pension Plan Trust Fund, Russell Investments Group Ltd., and Alps Advisors Inc.. Company insiders that have sold ImmunoGen company stock in the last year include Craig Barrows, David G Foster, Mark J Enyedy, and Thomas Ryll. View insider buying and selling activity for ImmunoGen. Which institutional investors are buying ImmunoGen stock? IMGN stock was bought by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Assenagon Asset Management S.A., Skandinaviska Enskilda Banken AB publ, Principal Financial Group Inc., Principal Financial Group Inc., HighTower Advisors LLC, Hussman Strategic Advisors Inc., and Two Sigma Advisers LP. View insider buying and selling activity for ImmunoGen. How do I buy shares of ImmunoGen? Shares of IMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is ImmunoGen's stock price today? One share of IMGN stock can currently be purchased for approximately $4.07. How big of a company is ImmunoGen? ImmunoGen has a market capitalization of $710.39 million and generates $82.27 million in revenue each year. The biotechnology company earns $-104,130,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. ImmunoGen employs 296 workers across the globe. What is ImmunoGen's official website? The official website for ImmunoGen is www.immunogen.com. How can I contact ImmunoGen? ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-895-0600 or via email at [email protected] This page was last updated on 9/19/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
